Kite Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Kite Pharma (KITE) PT Raised to $120 at Canaccord Genuity
August 8, 2017 12:51 PM EDTCanaccord Genuity raised its price target on Kite Pharma (NASDAQ: KITE) to $120.00 (from $115.00) while maintaining a Buy rating.
Analyst John Newman with the coverage.
... MoreKite Pharma (KITE) Post Smaller Q2 Loss on Higher Revs
August 8, 2017 8:01 AM EDTKite Pharma (NASDAQ: KITE) reported Q2 EPS of ($1.50), $0.48 better than the analyst estimate of ($1.98). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $9.59 million.
"We've continued to make significant progress on key clinical and commercial milestones in the... More
